Arzerra (ofatumumab) 1000 mg/50 mL concentrate for solution for infusion — original (GSK, United Kingdom) Previously untreated chronic lymphocytic leukemia (CLL) Targeted cancer therapy. Drug delivery from Europe and beyond, within 4-5 days, with proper storage conditions.

Price upon request

Indications

• Previously untreated chronic lymphocytic leukemia (CLL): Arzerra, along with chlorambucil or bendamuztine, is indicated for the treatment of patients with CLL who have not received prior treatment and for whom fludarabine therapy is not an option.
• Refractory CLL: Arzerra is indicated for the treatment of patients with CLL who have failed fludarabine and alemtuzumab.